Publications
Detailed Information
Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sang Gyu | - |
dc.contributor.author | Jee, Young Geon | - |
dc.contributor.author | Chung, Hyun Chul | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.contributor.author | Ro, Jungsil | - |
dc.contributor.author | Im, Young-Hyuck | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.date.accessioned | 2012-05-23T07:14:18Z | - |
dc.date.available | 2012-05-23T07:14:18Z | - |
dc.date.created | 2021-11-23 | - |
dc.date.created | 2021-11-23 | - |
dc.date.issued | 2009-04 | - |
dc.identifier.citation | Breast Cancer Research and Treatment, Vol.114 No.3, pp.589-595 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.other | 148340 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76341 | - |
dc.description.abstract | Background This study evaluated the incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) of TAC compared with FAC following primary surgery for node positive breast cancer patients in Korea. Materials and methods A cost-effectiveness analysis was performed using the Markov model from the combined view of Korean National Health Insurance and patients. The model allowed assessment from the beginning of the first cycle of adjuvant chemotherapy following primary surgery until death. Relevant clinical data were obtained from the clinical trial BCIRG 001 and data for local treatment patterns and direct medical costs were obtained from three Korean hospitals. Results Over a life time horizon, the life expectancy of TAC was 0.9 years longer than that of FAC. The ICER was 8,025,879 Korean won (KW, a,not sign6,573) per life year gained and the ICUR was 8,885,794 KW (a,not sign7,277) per QALY gained when the cost and effectiveness were discounted at 5%. The model was most sensitive to the percent patient receiving prophylactic granulocyte colony stimulating factor (G-CSF) in TAC arm and the ICUR was 12,119,561 KW (a,not sign9,926) when assuming 100%. Conclusions TAC appears to be cost-effective in the management of early breast cancer in Korea. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | Kluwer Academic Publishers | - |
dc.title | Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC) | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s10549-008-0035-0 | - |
dc.citation.journaltitle | Breast Cancer Research and Treatment | - |
dc.description.citedreference | Kimura M, 2007, BREAST CANCER RES TR, V106, P407, DOI 10.1007/s10549-007-9510-2 | - |
dc.description.citedreference | YOUNIS T, 2007, BREAST CANC RES 0510 | - |
dc.description.citedreference | BARRON JJ, 2007, BREAST CANC RES 0803 | - |
dc.description.citedreference | Kievit W, 2005, ANN ONCOL, V16, P1874, DOI 10.1093/annonc/mdi394 | - |
dc.description.citedreference | Trudeau M, 2005, LANCET ONCOL, V6, P886 | - |
dc.description.citedreference | Martin M, 2005, NEW ENGL J MED, V352, P2302 | - |
dc.description.citedreference | *KOR NAT HLTH INS, 2005, NAT HLTH INS FEE SCH | - |
dc.description.citedreference | Au HJ, 2005, BREAST CANCER RES TR, V94, pS218 | - |
dc.description.citedreference | Kruijshaar ME, 2004, EUR J PUBLIC HEALTH, V14, P141 | - |
dc.description.citedreference | Devlin N, 2004, HEALTH ECON, V13, P437, DOI 10.1002/hec.864 | - |
dc.description.citedreference | *KOR NAT STAT OFF, 2004, ANN REP CAUS DEATH S | - |
dc.description.citedreference | Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576 | - |
dc.description.citedreference | Ubel PA, 2003, ARCH INTERN MED, V163, P1637 | - |
dc.description.citedreference | Radice D, 2003, PHARMACOECONOMICS, V21, P383 | - |
dc.description.citedreference | Lee JH, 2002, J CLIN ONCOL, V20, P2713, DOI 10.1200/JCO.2002.07.008 | - |
dc.description.citedreference | BRINTON L, 2002, CANC BREAST, P111 | - |
dc.description.citedreference | George B, 2001, PHARMACOECONOMICS, V19, P1103 | - |
dc.description.citedreference | Demicheli R, 1999, BREAST CANCER RES TR, V53, P209 | - |
dc.description.citedreference | *BUR HLTH INF POL, 1999, WISC CANC INC MORT | - |
dc.description.citedreference | Saphner T, 1996, J CLIN ONCOL, V14, P2738 | - |
dc.description.citedreference | KEELER E, 1995, VALUING HLTH CARE, P185 | - |
dc.description.citedreference | SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322 | - |
dc.description.tc | 16 | - |
dc.identifier.wosid | 000263786300023 | - |
dc.identifier.scopusid | 2-s2.0-61449218102 | - |
dc.citation.endpage | 595 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 589 | - |
dc.citation.volume | 114 | - |
dc.identifier.sci | 000263786300023 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | DECISION-MAKING | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | RATES | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | LIFE | - |
dc.subject.keywordAuthor | Adjuvant therapy | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Cost-effectiveness | - |
dc.subject.keywordAuthor | Taxanes | - |
dc.subject.keywordAuthor | Korean | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.